EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide

Takashi Matsuoka iD, Aiko Sugiyama, Yoshifumi Miyawaki, Yusuke Hidaka, Yukiko Okuno iD, Hiroaki Sakai, Hiroki Tanaka, Kiyotsugu Yoshikawa, Tomohiro Fukui, Kei Mizuno, Takayuki Sumiyoshi, Takayuki Goto und 4 weitere

Cancer Science · 2024

DOI: 10.1111/cas.15984 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Takashi Matsuoka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Benzamides, Phenylthiohydantoin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen‐deprivation therapy is a standard treatment for advanced prostate cancer. However, most patients eventually acquire resistance and progress to castration‐resistant prostate cancer (CRPC). In this study, we established new CRPC cell lines, AILNCaP14 and AILNCaP15, from LNCaP cells under androgen‐deprived conditions. Unlike most pre‐existing CRPC cell lines, both cell lines expressed higher levels of androgen receptor (AR) and prostate‐specific antigen (PSA) than parental LNCaP cells. Moreover, these cells exhibited primary resistance to enzalutamide. Since AR signaling plays a significant role in the development of CRPC, PSA promoter sequences fused with GFP were introduced into AILNCaP14 cells to conduct GFP fluorescence‐based chemical screening. We identified flavopiridol, a broad‐spectrum CDK inhibitor, as a candidate drug that could repress AR transactivation of CRPC cells, presumably through the inhibition of phosphorylation of AR on the serine 81 residue (pAR Ser81 ). Importantly, this broad‐spectrum CDK inhibitor inhibited the proliferation of AILNCaP14 cells both in vitro and in vivo. Moreover, a newly developed liver metastatic model using AILNCaP15 cells revealed that the compound attenuated tumor growth of CRPC harboring highly metastatic properties. Finally, we developed a patient‐derived xenograft (PDX) model of CRPC and DCaP CR from a patient presenting therapeutic resistance to enzalutamide, abiraterone, and docetaxel. Flavopiridol successfully suppressed the tumor growth of CRPC in this PDX model. Since AR Ser81 was found to be phosphorylated in clinical CRPC samples, our data suggested that broad‐spectrum CDK inhibitors might be a potent candidate drug for the treatment of CRPC, including those exhibiting primary resistance to enzalutamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBenzamidesPhenylthiohydantoinMaleHumansProstate-Specific AntigenAndrogen AntagonistsAndrogensDrug Resistance, NeoplasmReceptors, AndrogenNitrilesCell Line, Tumor

Stichwörter der Autor:innen

CDK inhibitorandrogen receptorprostate cancerserine 81 phosphorylation

Substanzen

Prostate-Specific AntigenenzalutamideAndrogen AntagonistsAndrogensReceptors, AndrogenNitrilesBenzamidesPhenylthiohydantoin

Autor:innen und Institutionen

  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • DSK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Medical Research Support Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Laboratory of Pharmacotherapy, Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
  • Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Urology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Takashi Matsuoka, Yukiko Okuno, Takashi Kobayashi

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Matsuoka, T., Sugiyama, A., Miyawaki, Y., Hidaka, Y., Okuno, Y., Sakai, H., Tanaka, H., Yoshikawa, K., Fukui, T., Mizuno, K., Sumiyoshi, T., Goto, T., Inoue, T., Akamatsu, S., Kobayashi, T., & Nakamura, E. (2024). Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide. Cancer Science. https://doi.org/10.1111/cas.15984

Vancouver

Matsuoka T, Sugiyama A, Miyawaki Y, Hidaka Y, Okuno Y, Sakai H, et al. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide. Cancer Science. 2024. doi:10.1111/cas.15984

BibTeX
@article{Matsuoka2024,
  author = {Matsuoka, Takashi and Sugiyama, Aiko and Miyawaki, Yoshifumi and Hidaka, Yusuke and Okuno, Yukiko and Sakai, Hiroaki and Tanaka, Hiroki and Yoshikawa, Kiyotsugu and Fukui, Tomohiro and Mizuno, Kei and Sumiyoshi, Takayuki and Goto, Takayuki and Inoue, Takahiro and Akamatsu, Shusuke and Kobayashi, Takashi and Nakamura, Eijiro},
  title = {Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.15984}
}
Kostenlos starten →